A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).

MLA

Ozaka, Masato, et al. “A Randomised Phase II Study of Modified FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Locally Advanced Pancreatic Cancer (JCOG1407).” European Journal of Cancer, vol. 181, Mar. 2023, pp. 135–44. EBSCOhost, https://doi.org/10.1016/j.ejca.2022.12.014.

APA

Ozaka, M., Nakachi, K., Kobayashi, S., Ohba, A., Imaoka, H., Terashima, T., Ishii, H., Mizusawa, J., Katayama, H., Kataoka, T., Okusaka, T., Ikeda, M., Sasahira, N., Miwa, H., Mizukoshi, E., Okano, N., Mizuno, N., Yamamoto, T., Komatsu, Y., & Todaka, A. (2023). A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). European Journal of Cancer, 181, 135–144. https://doi.org/10.1016/j.ejca.2022.12.014

Chicago

Ozaka, Masato, Kohei Nakachi, Satoshi Kobayashi, Akihiro Ohba, Hiroshi Imaoka, Takeshi Terashima, Hiroshi Ishii, et al. 2023. “A Randomised Phase II Study of Modified FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Locally Advanced Pancreatic Cancer (JCOG1407).” European Journal of Cancer 181 (March): 135–44. doi:10.1016/j.ejca.2022.12.014.